UK markets open in 7 hours 59 minutes

Reviva Pharmaceuticals Holdings, Inc. (RVPH)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.0500+0.0693 (+7.07%)
At close: 04:00PM EDT
0.9705 -0.08 (-7.57%)
After hours: 06:30PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.9807
Open1.0000
Bid1.0000 x 100
Ask1.0900 x 100
Day's range0.9600 - 1.3000
52-week range0.9500 - 6.8000
Volume1,695,387
Avg. volume262,400
Market cap31.308M
Beta (5Y monthly)-0.10
PE ratio (TTM)N/A
EPS (TTM)-1.5900
Earnings date12 Aug 2024 - 16 Aug 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est13.50
  • GlobeNewswire

    Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Hypertension

    - Patent covers brilaroxazine use for treating pulmonary hypertension (PH), pulmonary arterial hypertension (PAH) in any patients including treating PH in patients with chronic obstructive pulmonary disease (COPD) or sickle cell disease (SCD) -Similar patents have also been granted in key markets around the world including the United States, China, and Japan -Brilaroxazine has a novel mechanism of action for treating the underlying disruption in serotonin signaling implicated in the pathogenesis

  • GlobeNewswire

    Reviva Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

    CUPERTINO, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that it has closed its previously announced registered direct offering for the sale and issuance of 1,898,734 shares of the Company’s common stock and warrants to

  • GlobeNewswire

    Reviva Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

    CUPERTINO, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that it has entered into a definitive agreement for the sale and issuance of 1,898,734 shares of the Company’s common stock and warrants to purchase up to 1,898,73